Early non-invasive ventilation and high-flow nasal oxygen therapy for preventing endotracheal intubation in hypoxemic blunt chest trauma patients: the OptiTHO randomized trial. - Biology of Cardiovascular Diseases Accéder directement au contenu
Article Dans Une Revue Critical Care Année : 2023

Early non-invasive ventilation and high-flow nasal oxygen therapy for preventing endotracheal intubation in hypoxemic blunt chest trauma patients: the OptiTHO randomized trial.

Benjamin Rieu
  • Fonction : Auteur
Antoine Benard
  • Fonction : Auteur
Kilian Trin
  • Fonction : Auteur
Laurent Petit
  • Fonction : Auteur
Alexandre Massri
  • Fonction : Auteur
Guillaume Rousseau
  • Fonction : Auteur
David Tran Van
  • Fonction : Auteur
Marie Reynaud Salard
  • Fonction : Auteur
Albrice Levrat
  • Fonction : Auteur
Laurent Muller
  • Fonction : Auteur
Damien Marie
  • Fonction : Auteur
Claire Dahyot-Fizelier
  • Fonction : Auteur
Julien Pottecher
  • Fonction : Auteur
Thomas Godet
  • Fonction : Auteur

Résumé

Background: The benefit–risk ratio of prophylactic non-invasive ventilation (NIV) and high-flow nasal oxygen therapy (HFNC-O2) during the early stage of blunt chest trauma remains controversial because of limited data. The main objective of this study was to compare the rate of endotracheal intubation between two NIV strategies in high-risk blunt chest trauma patients. Methods: The OptiTHO trial was a randomized, open-label, multicenter trial over a two-year period. Every adult patients admitted in intensive care unit within 48 h after a high-risk blunt chest trauma (Thoracic Trauma Severity Score ≥ 8), an estimated PaO2/FiO2 ratio < 300 and no evidence of acute respiratory failure were eligible for study enrollment (Clinical Trial Registration: NCT03943914). The primary objective was to compare the rate of endotracheal intubation for delayed respiratory failure between two NIV strategies: i) a prompt association of HFNC-O2 and “early” NIV in every patient for at least 48 h with vs. ii) the standard of care associating COT and “late” NIV, indicated in patients with respiratory deterioration and/or PaO2/FiO2 ratio ≤ 200 mmHg. Secondary outcomes were the occurrence of chest trauma-related complications (pulmonary infection, delayed hemothorax or moderate-to-severe ARDS). Results: Study enrollment was stopped for futility after a 2-year study period and randomization of 141 patients. Overall, 11 patients (7.8%) required endotracheal intubation for delayed respiratory failure. The rate of endotracheal intubation was not significantly lower in patients treated with the experimental strategy (7% [5/71]) when compared to the control group (8.6% [6/70]), with an adjusted OR = 0.72 (95%IC: 0.20–2.43), p = 0.60. The occurrence of pulmonary infection, delayed hemothorax or delayed ARDS was not significantly lower in patients treated by the experimental strategy (adjusted OR = 1.99 [95%IC: 0.73–5.89], p = 0.18, 0.85 [95%IC: 0.33–2.20], p = 0.74 and 2.14 [95%IC: 0.36–20.77], p = 0.41, respectively). Conclusion: A prompt association of HFNC-O2 with preventive NIV did not reduce the rate of endotracheal intubation or secondary respiratory complications when compared to COT and late NIV in high-risk blunt chest trauma patients with non-severe hypoxemia and no sign of acute respiratory failure. Clinical Trial Registration: NCT03943914, Registered 7 May 2019.
Fichier principal
Vignette du fichier
BMC_Critical Care_2023_CARRIE.pdf (1.36 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04095038 , version 1 (11-05-2023)

Licence

Paternité

Identifiants

  • HAL Id : hal-04095038 , version 1

Citer

Cédric Carrié, Benjamin Rieu, Antoine Benard, Kilian Trin, Laurent Petit, et al.. Early non-invasive ventilation and high-flow nasal oxygen therapy for preventing endotracheal intubation in hypoxemic blunt chest trauma patients: the OptiTHO randomized trial.. Critical Care, 2023, 27 (1), pp.163. ⟨hal-04095038⟩
23 Consultations
5 Téléchargements

Partager

Gmail Facebook X LinkedIn More